|
|
||||||||


Departments of
*
Pharmacology and Therapeutics and
Immunology, University of Liverpool, Liverpool, United Kingdom; and
Respiratory and Inflammation Research Area, AstraZeneca, Alderley Park, United Kingdom
NO is antiproliferative for T cells and other immune cells, but there is debate over whether it influences cytokine expression and if so whether it shows cytokine selectivity. Furthermore, the NO effect may depend on exposure time. To address these issues, we precultured human PBMC with the NO donors S-nitrosoglutathione (a natural storage form of NO) or S-nitroso-N-acetyl-D-penicillamine for up to 48 h before cell activation and then monitored proliferation and cytokine and chemokine expression. S-nitrosoglutathione or S-nitroso-N-acetyl-D-penicillamine, but not their non-NO-releasing analogues, inhibited proliferation induced by PHA or IL-2, the effect declining progressively from 48 to 0 h pre-exposure to the mitogen. This was accompanied by reduced PHA-induced IL-2 release and reduced IL-2, IFN-
, and IL-13 mRNA expression. In contrast, NO did not influence PHA-induced expression of mRNA for the chemokines lymphotactin, RANTES, IFN-
-inducible protein, macrophage-inhibitory protein-1
, macrophage-inhibitory protein-1
, macrophage chemoattractant protein-1, and IL-8 or release of RANTES or IL-8. The NO effects were not toxic and were not accompanied by changes in PHA-induced CD25 expression. We conclude that exposure time to NO is critical to altered PBMC responsiveness and that NO inhibits expression of both Th1 and Th2 cytokines but not chemokines.
This article has been cited by other articles:
![]() |
W. Niedbala, B. Cai, H. Liu, N. Pitman, L. Chang, and F. Y. Liew Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40 PNAS, September 25, 2007; 104(39): 15478 - 15483. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Talmadge Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5243 - 5248. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-O. Pae, G.-S. Oh, B.-M. Choi, Y.-M. Kim, and H.-T. Chung A Molecular Cascade Showing Nitric Oxide-Heme Oxygenase-1-Vascular Endothelial Growth Factor-Interleukin-8 Sequence in Human Endothelial Cells Endocrinology, May 1, 2005; 146(5): 2229 - 2238. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Stechmiller, B. Langkamp-Henken, B. Childress, K. A. Herrlinger-Garcia, J. Hudgens, L. Tian, S. S. Percival, and R. Steely Arginine Supplementation Does Not Enhance Serum Nitric Oxide Levels in Elderly Nursing Home Residents With Pressure Ulcers Biol Res Nurs, April 1, 2005; 6(4): 289 - 299. [Abstract] [PDF] |
||||
![]() |
B. J. Davis, B. F. Flanagan, A. M. Gilfillan, D. D. Metcalfe, and J. W. Coleman Nitric Oxide Inhibits IgE-Dependent Cytokine Production and Fos and Jun Activation in Mast Cells J. Immunol., December 1, 2004; 173(11): 6914 - 6920. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Lind Arginine and Cancer J. Nutr., October 1, 2004; 134(10): 2837S - 2841S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gilchrist, S. D. McCauley, and A. D. Befus Expression, localization, and regulation of NOS in human mast cell lines: effects on leukotriene production Blood, July 15, 2004; 104(2): 462 - 469. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |